Memantine does not influence AChE inhibition in rat brain by donepezil or rivastigmine but does with DFP and metrifonate in in vivo studies

Drug Development Research

Volumn 64, Issue 1, 2005, Pages 71-81

  Gupta, Ramesh C ^a   Dekundy, A ^b  

^a MURRAY STATE UNIVERSITY   (United States)

^b Merz Pharmaceuticals GmbH   (France)

Author keywords

Acetylcholinesterase; Brain; Donepezil; Memantine; Rivastigmine

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; DYFLOS; MEMANTINE; METRIFONATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RIVASTIGMINE;

ACETYLCHOLINESTERASE INHIBITION; ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN REGION; CHOLINESTERASE INHIBITION; CONTROLLED STUDY; DEMENTIA; DOSE TIME EFFECT RELATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FASCICULATION; HIPPOCAMPUS; MALE; NONHUMAN; RAT; TREMOR;

EID: 18044388911     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10422     Document Type: Article

References (60)

1. Antonijevic B, Maksimovic M, Kilibarda V, et al. 2002. Efficacy of oximes and adamantanes against soman poisoning in mice. Proceedings of the Chemical and Biological Medical Treatment Symposium 3rd. Spiez, Switzerland.
2. Areosa-Sastre A, Sherriff F. 2003. Memantine for dementia. Cochrane Rev: The Cochrane Library, Issue 1.
3. Ballard CG. 2002. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 47:64-70.
4. Bartus RT, Dean RLI, Beer B, Lippa AS. 1982. The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-417.
5. Becker R, Giacobini E. 1988. Advances in the therapy of Alzheimer's disease: issues in the study and development of cholinomimetic therapies. In: Giacobini E, Becker R, editors. Current research in Alzheimer therapy. New York: Taylor and Francis, p 113-122.
6. Cacabelos R, Takeda M, Winblad B. 1999. The glutamatergic system and neurodegeneration in dementia: preventative strategies in Alzheimer's disease. Int J Geriatr Psychiatr 14:3-47.
7. Coyle JT, Price DL, DeLong MR. 1983. Alzheimer's disease: a disorder of cortical cholinergic neurons. Science 219:1184-1190.
8. Danysz W, Parsons CG, Möbius H J, Stöffler A, Quack G. 2000. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease-a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res 2:85-97.
9. Darvesh S, Walsh R, Kumar R, et al. 2003. Kinetic properties of human acetylcholinesterase and butyrylcholinesterase in the presence of drugs for Alzheimer's disease. Alzheimer Dis Assoc Disord 17:117-126.
10. Enz A, Gentsch C. 2004. Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain. NeuroPharmacology 47:408-413.
11. Farlow MR, Tariot PN, Grossberg GT, Gergel I, Graham S, Jin J. 2003. Memantine/donepezil dual therapy is superior to placebo/ donepezil therapy for treatment of moderate to severe Alzheimer's disease. Neurology 60(suppl 1):S48.003.
12. Gauthier S, Lebanc R, Quirion R, Carlsson G, Beaulieu M, et al. 1986. Transmitter-replacement therapy in Alzheimer's disease using intracerebroventricular infusions of receptor agonists. Can J Neurol Sci 13:394-402.
13. Giacobini E. 2000. Cholinesterase inhibitors: from the calabar bean to Alzheimer therapy. In: Giacobini E, editor. Cholinesterases and cholinesterase inhibitors. London: Martin Dunits Ltd. p 181-226.
14. Giacobini E, Becker R, McIlhany M. 1988. Present progress and future development in treatment of Alzheimer's disease. In: Proceedings of the International Symposium on Alzheimer's Disease. Finland: Kuopio University, p 40-49.
15. Giacobini E, Spiegel R, Enz A, Verff AE, Cutler NR. 2002. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. J Neural Transm 109:1053-1065.
16. Gortelmeyer R, Erbler H. 1992. Memantine in the treatment of mild to moderate dementia syndrome. Argneimittelforschung 42:904-913.
17. Grossberg GT, Desai AK. 2003. Management of Alzheimer's disease. J Gerontol (Med Sci) 58A:331-353.
18. Grutzendler J, Morris JC. 2001. Cholinesterase inhibitors for Alzheimer's disease. Drugs 61:41-52.
19. Guillozet AL, Smiley JF, Mash DC, Mesulam MM. 1997. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 42:909-918.
20. Gupta RC. 1994. Mechanistic and clinical approaches in antidotal treatment with memantine and atropine against oxamyl and methomyl acute toxicity. Ind J Toxicol 1:1-10.
21. Gupta RC, Dettbarn W-D. 1992. Potential of memantine, d-tubocurarine, and atropine in preventing acute toxic myopathy induced by organophosphate nerve agents: soman, sarin, tabun, and VX. Neurotoxicology 13:649-662.
22. Gupta RC, Goad JT. 2000. Role of high-energy phosphates and their metabolites in protection of carbofuran-induced biochemical changes in diaphragm muscle by memantine. Arch Toxicol 74:13-20.
23. Gupta RC, Kadel WL. 1989. Prevention and antagonism of acute carbofuran intoxication by memantine and atropine. J Toxicol Environ Health 28:111-122.
24. Gupta RC, Kadel WL. 1990. Methyl parathion acute toxicity: prophylaxis and therapy with memantine and atropine. Arch Int Pharmacodyn Ther 305:208-221.
25. Gupta RC, Kadel WL. 1991. Novel effects of memantine in antagonizing acute aldicarb toxicity: mechanistic and applied considerations. Drug Dev Res 24:329-341.
26. Gupta RC, Milatovic D, Dettbarn W-D. 2000. Cholinergic and noncholinergic brain biomarkers of insecticide exposure and effects. Hum Exp Toxicol 19:297-308.
27. Harbaugh RE, Roberts DW, Coombs DW, et al. 1984. Preliminary report: intracranial cholinergic drug infusion in patients with Alzheimer's disease. Neurosurgery 15:514-517.
28. Hartmann S, Möbius HJ. 2003. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol 18:81-85.
29. Hecht BK, Hecht F. 2004. FDA approves memantine (Namenda) for Alzheimer's disease, www.medicinnet.com.
30. Ibach B, Haen E. 2004. Acetylcholinesterase inhibition in Alzheimer's disease. Curr Pharmaceut Design 10:231-251.
31. Krall WJ, Sramek JJ, Cutler NR. 1999. Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease. Ann Pharmacother 33:441-450.
32. Levy A, Brandies R, Trives TA, et al. 1994. Transdermal physostigmine in the treatment of Alzheimer's disease. Alzheimer's Dis Assoc Disord 8:15-21.
33. Little A, Levy R, Chuaqui-Kidd P, Hand D. 1985. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease. J Neurol 48:736-742.
34. Masuo K, Enomoto K-I, Maeno T. 1986. Effects of memantine on the frog neuromuscular junction. Eur J Pharmacol 130:187-195.
35. McLean MJ, Gupta RC, Dettbarn W-D, Wamil AW. 1992. Prophylactic and therapeutic efficacy of memantine against seizures by soman in the rat. Toxicol Appl Pharmacol 111:95-103.
36. Möbius HJ. 2003. Memantine: update on the current evidence. Int J Geriatr Psychiatry 18:S47-S54.
37. Murphy MF, Sramek JJ, Kurtz MM, et al. 1998. Optimizing the development of the next generation of compounds for Alzheimer's disease. London: Greenwich Medical Media Ltd.
38. Ogura H, Kosasa T, Kuriya Y, et al. 2000. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase inhibitors in vitro. Methods Find Exp Clin Pharmacol 22:609-613.
39. Orgogozo JM, Rigand AS, Stöffler A, Möbius HJ, Forette F. 2002. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized placebo-controlled trial (MMM 300). Stroke 33:1834-1839.
40. Parsons CG, Danysz W, Quack G. 1999. Memantine is a clinically well-tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 38:735-767.
41. Penn RD, Martin EM, Wilson RS, Fox JH, Savoy SM. 1988. Intraventricular bethanechol infusion for Alzheimer's disease: results of double-blind and escalating dose trials. Neurology 38:219-222.
42. Polinsky RJ. 1998. Clinical pharmacology of rivastigmine: a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 20:634-647.
43. Pope CN. 1999. Organophosphorus pesticides: do they all have the same mechanism of toxicity? J Toxicol Environ Health Part B 2:161-181.
44. Reisberg B, Doody R, Stöffler A, et al. 2003. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348:1333-1341.
45. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. 1998. A 24-week, double-blind, placebo-controlled trial of donezepil in patients with Alzheimer's disease. Donezepil Study Group. Neurology 50:136-145.
46. Scali C, Casamenti F, Bellucci A, Costagli, C, Schmidt B, Pepu G. 2002. Effect of subchronic administration of metrifonate, rivastigmine, and donepezil on brain acetylcholine in aged F344 rats. J Neurotransmission 109:7-8.
47. Sramek JJ, Zarotsky V, Cutler NR. 2002. Review of drug development and therapeutic role of cholinesterase inhibitors in Alzheimer's disease. Drug Dev Res 56:347-353.
48. Stojiljkovic MP, Maksomovic M, Kilibarda V, et al. 2002. Memantine treatment improves antidotal efficacy of atropine, HI-6 and diazepam in rats poisoned with soman. Proceedings of the Chemical and Biological Medical Treatment Symposium 3rd. Spiez, Switzerland.
49. Summers WK, Majorski LV, Marsh GM, Tachild K, Kling A. 1986. Oral tetrahydroaminoacridine in long-term treatment of senile dementia. Alzheimer type. N Engl J Med 315:1241-1245.
50. Tariot PN, Farlow MR, Grossberg GT, et al. 2004. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA 291:317-324.
51. Taylor P. 1998. Development of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease. Neurology 51(suppl 1): S30-S35.
52. Thal LJ, Masur DM, Sharpless NS, Fuld PA, Davies P. 1986. Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatr 10:627-636.
53. Weinstock M. 1999. Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimer's disease. CNS Drugs 12:307-323.
54. Wengel SP, Roccaforte WH, Burke WJ, Bayer BL, McNeilly BP, Knop D. 1998. Behavioral complications associated with donepezil. Am J Psychiatry 155:1632-1633.
55. Wenk GL, Quack G, Möbius HJ, Danysz W. 2000. NO interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci 66:1079-1083.
56. Weseman W, Sontag KH, Maj J. 1983. Zur pharmacodynamic und pharmacokinetic des memantine. Azneimettel Forschung 33:1122-1134.
57. Wesemann W, Eckenna O. 1982. Effect of 1-aminoadamantanes on the MAO activity in brain, liver and kidney of the rat. Arzneimittel Forschung 32:1241-1243.
58. Wilcock GK. 2003. Memantine for the treatment of dementia. Lancet Neurol 2:503-505.
59. Wilkinson D. 2001. Head to head comparison of donepezil and rivastigmine: ease of use and efficacy during a 12 week study. Adv Stud Med 1:327-329.
60. Wynn ZJ, Cummings JL. 2004. Cholinesterase inhibitor therapies and neuropsychiatrie manifestations of Alzheimer's disease. Dement Geriatr Cogn Disord 17:100-108.